Scholars Central

Conference abstractPublished 18 Jun 2018

The story of glatiramer acetate (copaxone) in the treatment of multiple sclerosis - the potential for neuroprotection by immunomodulatory treatment

Authors: Rina Aharoni

Weizmann Institute of Science, Israel

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Multiple sclerosis (MS) is currently recognized as complex diseases in which inflammatory reactivity in the central nervous system (CNS) results in demyelination, axonal and neuronal pathology. Treatment strategies thus aim to reduce the detrimental inflammation and induce neuroprotective repair processes. The synthetic copolymer Copaxone (glatiramer acetate, GA), an approved drug for the treatment of MS, is the first and so far the only therapeutic agent to have a copolymer as its active ingredient. Using the animal model of MS - experimental autoimmune encephalomyelitis (EAE), the mechanism of action of GA was elucidated. These studies indicated that GA treatment generates immunomodulatory shift from the inflammatory towards the anti-inflammatory pathways, such as Th2-cells that cross the blood brain barrier (BBB) and secrete in situ anti-inflammatory cytokines, as well as T-regulatory cells (Tregs) that suppress the disease. The consequences of GA treatment on the CNS injury inflicted by the disease were studied using immunohistochemistry, electron microscopy, and magnetic resonance imaging. These analyses revealed reduced demyelination and neuro-axonal damages, as well as neuroprotective repair processes such as neurotrophic factors secretion, remyelination and neurogenesis. These combined findings indicate that immunomodulatory treatment can counteract the neurodegenerative disease course, supporting linkage between immunomodulation, neuroprotection and therapeutic activity in the CNS. Recent Publications: 1. R Eilam, M Segal, R Malach, M Sela, R Arnon and R Aharoni (2018) Astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosis Glia 66:1098-1117. 2. R Aharoni, C Rosen, E Shezen, D Bar-Lev, O Golan, Y Reisner, M Sela, R Arnon (2016) Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis. Journal of Neuroimmunology. 301, 7–11. 3. R Aharoni (2015) Remyelination in multiple sclerosis: realizing a long standing challenge. Expert Review of Neurotherapeutics. 22(41), 1-4. 4. R Aharoni (2015) Animal models of multiple sclerosis: imperfect but imperative Journal of Multiple Sclerosis 2(4), 2-4. 5. RAharoni(2014) Immunomodulation, neuroprotection and remyelination - The fundamental therapeutic effects of glatiramer acetate: A critical review. Journal of Autoimmunity. 54, 81-92.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels